Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: PYXS

Pyxis Oncology, Inc.

Healthcare | Biotechnology

No licensed closing price on file for PYXS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-1.28

Pyxis Oncology, Inc. (NASDAQ: PYXS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:14 UTC.

What Pyxis Oncology, Inc. does

Pyxis Oncology is a clinical-stage company developing micvotabart pelidotin (MICVO), an antibody-drug conjugate designed to target a specific fibronectin variant found in tumors but rarely in healthy tissues. MICVO works through a three-part mechanism: directly killing cancer cells, triggering a bystander effect that kills nearby cancer cells, and activating an immune response. The company is currently testing MICVO as both a standalone treatment and in combination with an existing immunotherapy in patients with head and neck squamous cell carcinoma and other solid tumors.

Summarized from Pyxis Oncology, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2025)$-1.28

Revenue, margins & earnings

FY2024: net loss $77M on revenue $16M$16MFY2024FY2025: net loss $80M on revenue $14M$14MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-09
  • 2026-10-0910% OwnerCommon Stock Purchase WarrantPurchase7,172,000—
  • 2026-10-0210% OwnerPurchase5,517,000—
  • 2026-10-0210% OwnerCommon Stock Purchase WarrantPurchase7,546,766—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Pyxis Oncology, Inc. do?

Pyxis Oncology is a clinical-stage company developing micvotabart pelidotin (MICVO), an antibody-drug conjugate designed to target a specific fibronectin variant found in tumors but rarely in healthy tissues.

When did PYXS last file with the SEC?

Pyxis Oncology, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:14 UTC. This page is also available as JSON at /api/data?ticker=PYXS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PYXS and 5,000+ tickers.

Create a free account — keep PYXS
For your agent
GET /api/data?ticker=PYXS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt